Ocular Therapeutix
OCUL
75 hedge funds and large institutions have $70.2M invested in Ocular Therapeutix in 2019 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 29 increasing their positions, 12 reducing their positions, and 4 closing their positions.
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
142% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 12
15% more call options, than puts
Call options by funds: $506K | Put options by funds: $441K
10% more funds holding
Funds holding: 68 → 75 (+7)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
4.08% less ownership
Funds ownership: 53% → 48.92% (-4.1%)
30% less capital invested
Capital invested by funds: $99.9M → $70.2M (-$29.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DAM
Deltec Asset Management
New York
|
+$2.65M |
| 2 |
MWP
MYCIO Wealth Partners
Philadelphia,
Pennsylvania
|
+$1.2M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$622K |
| 4 |
BlackRock
New York
|
+$592K |
| 5 |
State Street
Boston,
Massachusetts
|
+$412K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.8M |
| 2 |
JP Morgan Chase
New York
|
-$1.25M |
| 3 |
Man Group
London,
United Kingdom
|
-$1.11M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$782K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$314K |
OCUL Hedge Fund Activity: Q3 2019 in Review
75 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q3 2019, worth a combined $70.2M — down 30% from $99.9M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new OCUL positions and 4 closed out — a net gain of 7 holders — while 29 added to existing stakes and 12 trimmed.
The largest buyer was Deltec Asset Management, adding an estimated $2.65M. The largest seller was Fidelity Investments, cutting an estimated $1.8M.
- 75 institutional investors held Ocular Therapeutix (OCUL) as of Q3 2019, up from 68 in Q2 2019.
- Funds reported $70.2M of Ocular Therapeutix stock for Q3 2019, down 30% quarter-over-quarter.
- 11 funds opened new Ocular Therapeutix positions in Q3 2019 and 4 closed out, a net change of +7 holders.
- The largest Ocular Therapeutix buyer in Q3 2019 was Deltec Asset Management, an estimated $2.65M added.
- The largest Ocular Therapeutix seller in Q3 2019 was Fidelity Investments, an estimated $1.8M sold.
Based on aggregated 13F filings for Q3 2019.